TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06284642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urokinase
Description: On the basis of standard treatment for severe neurological conditions, within 24 hours of aneurysm treatment, lumbar drainage combined with intrathecal urokinase injection was started. 30,000 IU urokinase dissolved in 3 ml normal saline was injected into the subarachnoid space, 3 ml normal saline was rinsed into the tube, and the tube was clamped for observation for 2 hours, once a day, for 3 consecutive days. Lumbar cisternae drainage Cerebrospinal fluid is slowly and steadily drained at a rate of less than 8ml/h per hour, the daily drainage volume is not more than 200 ml, and the drainage time of lumbar cisternae is controlled within 7 to 10 days, not more than 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On the basis of standard treatment for severe neurological conditions, the treatment of lumbar drainage combined with intrathecal placebo saline injection was started within 24 hours after aneurysm treatment, 3 ml placebo was injected into the subarachnoid space, 3 ml normal saline was flushed into the tube, and the tube was observed for 2 hours, once a day for 3 consecutive days. Lumbar cisternae drainage Cerebrospinal fluid is slowly and steadily drained at a rate of less than 8ml/h per hour, the daily drainage volume is not more than 200 ml, and the drainage time of lumbar cisternae is controlled within 7 to 10 days, not more than 14 days.
Study: NCT06248268

Intervention type: OTHER
Intervention: (Neuro-)psychological assessment
Description: The measurement, which takes place 1 week after the informed consent, aims to determine the distinct (neuro-) psychological patterns of suicidal behavior versus suicidal ideation, in comparison to two control groups.

Intervention type: OTHER
Intervention: (Neuro-)psychological assessment
Description: The measurement, which takes place 1 week after the informed consent, aims to determine the distinct (neuro-) psychological patterns of suicidal behavior versus suicidal ideation, in comparison to two control groups.

Intervention type: OTHER
Intervention: (Neuro-)psychological assessment
Description: The measurement, which takes place 1 week after the informed consent, aims to determine the distinct (neuro-) psychological patterns of suicidal behavior versus suicidal ideation, in comparison to two control groups.

Intervention type: OTHER
Intervention: (Neuro-)psychological assessment
Description: The measurement, which takes place 1 week after the informed consent, aims to determine the distinct (neuro-) psychological patterns of suicidal behavior versus suicidal ideation, in comparison to two control groups.
Study: NCT04801667

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coronavac
Description: The CoronaVac is manufactured by Sinovac Life Sciences Co., Ltd. This vaccine contains the inactivated SARS-CoV-2 virus antigen and is administered intramuscularly.
Study: NCT04912336

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard coagulation profile
Description: prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), the fibrinogen level, plateletcount

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard coagulation profile
Description: prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), the fibrinogen level, plateletcount

Intervention type: DIAGNOSTIC_TEST
Intervention: Specific coagulation tests
Description: AT III, anti Xa, ACT, ROTEM

Intervention type: DIAGNOSTIC_TEST
Intervention: Specific coagulation tests
Description: AT III, anti Xa, ACT, ROTEM

Intervention type: OTHER
Intervention: Bleeding Scores
Description: Global Utilization of Streptokinase and Tpa for Occluded arteries definition of bleeding (GUSTO) AND Bleeding Academic Research Consortium Definition for Bleeding (BARC)

Intervention type: OTHER
Intervention: Bleeding Scores
Description: Global Utilization of Streptokinase and Tpa for Occluded arteries definition of bleeding (GUSTO) AND Bleeding Academic Research Consortium Definition for Bleeding (BARC)
Study: NCT06617273

Intervention type: DEVICE
Group type: OTHER
Intervention: Ophthalmosurgical handpiece with active anterior chamber pressure sensing and regulation
Description: Cataract surgery in patients with diabetic retinopathy using active anterior chamber pressure sensing and regulation

Intervention type: DEVICE
Group type: OTHER
Intervention: Ophthalmosurgical handpiece with active anterior chamber pressure sensing and regulation
Description: Cataract surgery in patients with diabetic retinopathy using active anterior chamber pressure sensing and regulation
Study: NCT05998551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: intrathecal injection of dexmedetomidine added to hyperbaric bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: intrathecal injection of fentanyl added to hyperbaric bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hcl 0.5% Inj
Description: intrathecal injection of hyperbaric bupivacaine only
Study: NCT05736536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chance2Act
Description: A Health education package that has been developed based on Transtheoretical Model to encourage behaviour change for weight loss among overweight/obese type 2 diabetes adults.
Study: NCT06676280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guideline-directed statin therapy
Description: as 2018 Cholesterol Clinical Practice Guidelines.
Study: NCT06339892

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Determination of HCMV DNA in plasma after DNAse digestion.
Description: Plasma will be tested after DNAse digestion for quantification of virion-associated HCMV DNA (defined as true breakthrough HCMV productive infection).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Determination of HCMV DNA in blood or plasma.
Description: HCMV DNA will be determined in blood or plasma without DNAse digestion, as per current clinical practice.
Study: NCT06624800

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder chuna treatment(posterior displacement, anterior displacement, or lateral displacement)
Description: The Shoulder Chuna therapy for the shoulder joint will be performed on the affected shoulder from the second day of hospitalization until the day before discharge.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Korean medical treatment
Description: acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Korean medical treatment
Description: acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
Study: NCT06328127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PATH
Description: PATH, a phone-delivered positive psychology intervention for patients who have undergone HSCT, consists of three 3-week modules. The first module focuses on gratitude and physical activity goal setting. The second module focuses on personal strengths and resources to enhance daily physical activity. The third module focuses on meaning and assessing barriers to physical activity. The third week of each module is an integration exercise dedicated to help participants explore practical ways of incorporating the themes for the given module into daily life. A trained interventionist will guide participants to complete each 30-minute weekly session.
Study: NCT06314763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20mg
Description: Single dose on day 1 and day 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib 960mg
Description: Daily dose from day 3 till day 16
Study: NCT06327386

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-FAPI#18F-FDG
Description: FAPI and FDG combined with PET/MR imaging in patients with gastric cancer after neoadjuvant therapy
Study: NCT06432556

Intervention type: GENETIC
Group type: OTHER
Intervention: scRNAseq
Description: A blood test tube (only for scRNAseq, 2 tubes of 10 ml per patient)

Intervention type: GENETIC
Group type: OTHER
Intervention: scRNAseq
Description: A blood test tube (only for scRNAseq, 2 tubes of 10 ml per patient)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: two Skin biopsies
Description: 2 skin biopsies from a lesional area

Intervention type: PROCEDURE
Group type: OTHER
Intervention: two Skin biopsies
Description: 2 skin biopsies from a lesional area

Intervention type: PROCEDURE
Group type: OTHER
Intervention: one Skin biopsies
Description: 1 skin biopsies from a lesional area

Intervention type: PROCEDURE
Group type: OTHER
Intervention: one Skin biopsies
Description: 1 skin biopsies from a lesional area
Study: NCT05197478

Intervention type: OTHER
Group type: OTHER
Intervention: Mini Nutritional Assessment ,Pıtsburg Sleep Qualıty Scale, Short Physical Activity Survey
Description: To evaluate the lifestyle before being infected with COVID 19, physical activity, nutrition and sleep habits were questioned.~To evaluate sleep habits; Pitsburg Sleep Quality Scale (PSQS) Nutritional habits: Mini Nutritional Assessment(MNA) Scale For the evaluation of physical activity; International Brief Physical Activity Questionnaire
Study: NCT05138549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Astaxanthin
Description: 12 mg oral astaxanthin supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo identical to astaxanthin supplement
Study: NCT06204419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XH-S002 （A）
Description: XH-S002 powder will be administered orally as per assigned treatment regimen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo（B）
Description: XH-S002 Placebo (matched) will be administered orally as per assigned treatment regimen.
Study: NCT05927831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grape Seed Extract
Description: Grape seed extract will be applied in the form of a gel on the tooth surface
Study: NCT06229119

Intervention type: DEVICE
Group type: OTHER
Intervention: Implantable Collamer Lens
Description: The EVO ICL lens is intended to be placed entirely within the posterior chamber directly behind the iris and in front of the anterior capsule of the human crystalline lens. When correctly positioned, the EVO ICL lens functions as a refractive element to optically reduce moderate to high myopia with or without astigmatism.
Study: NCT05927831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grape Seed Extract
Description: Grape seed extract will be applied in the form of a gel on the tooth surface

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: The device will be set at a wavelength of 810 nm, with a power output of 0.5 watts tip of diameter 300 μ in non-contact mode

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: The device will be set at a wavelength of 810 nm, with a power output of 0.5 watts tip of diameter 300 μ in non-contact mode
Study: NCT06710535

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Manipulation
Description: The participants will receive one session of manipulation if in the experimental group. It should be mentioned that the technique will be carried out by a physiotherapist with a history of more than 10 years of manual therapy. For instance, to correct right anterior innominate rotation, the participant will be made to lie on the side so that the affected side is upward. The physiotherapist will stand in front of the participant; first we will put their shoulders, pelvis and lower limbs in neutral position and place the right hand on the anterior superior iliac spine (ASIS) and the left hand on the ischium tuberosity and with a rotational movement of the hands, the physiotherapist will rotate the ilium posteriorly. At the end of the range, we will replace the position of hands and place the left forearm on the ischium tuberosity and place the right hand on the upper participant's shoulder and will move it toward the bed at the end of the range in exhalation a thrust will be executed.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Manipulation
Description: The participants will receive one session of sham manipulation if in the sham group. For instance, to correct right anterior innominate rotation, the participant will be made to lie on the side so that the affected side is upward. The physiotherapist will stand in front of the participant; first we will put their shoulders, pelvis and lower limbs in neutral position and place the right hand on the anterior superior iliac spine (ASIS) and the left hand on the ischium tuberosity and with a rotational movement of the hands, the physiotherapist will rotate the ilium posteriorly. At the end of the range, we will replace the position of hands and place the left forearm on the ischium tuberosity and place the right hand on the upper participant's shoulder and will move it toward the bed at the end of the range in exhalation, the physiotherapist will pretend to execute a thrust.
Study: NCT06275035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Oral Tablet
Description: Drug to preserve memory and neurocognitive dysfunction induced by radiation therapy
Study: NCT06712095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video capsule investigation
Description: Participants will undergo both a video capsule examination and a colonoscopy on the same day.
Study: NCT06714721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive peripheral magnetic stimulation
Description: Repetitive peripheral magnetic stimulation treatment will be performed with the BTL-6000 Super Inductive System Elite available in our clinic. rPMS treatment will be adjusted to use the stimulus intensity above the motor threshold determined specifically for each patient by selecting the respiratory muscle strengthening protocol set in the device menu. The patient will be given a side-lying position, with the arms in front of the body and the elbows flexed, and the hips and knees in semiflexion. The applicator will be aligned to the diaphragm placement determined by ultrasonography (ninth intercostal space) and placed as close as possible to the skin, and rPMS will be applied for a total of 16 minutes, 8 minutes to the right diaphragm muscle and 8 minutes to the left diaphragm muscle. The treatment period is a total of 16 sessions according to the respiratory muscle strengthening protocol created by the company that developed the device.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: rPMS will be applied to the sham group as sham and the device will not be operated, the applicator of the device will be positioned on the right and left diaphragm muscle for a total of 16 minutes in the same way as the patients in the treatment group, and the sounds recorded during the operation of the device will be played to the patients as if the device was operating in the background. The patients will not know which group they are in.
Study: NCT06714305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group B will be assigned to rotary instrumentation.
Description: group B, NiTi rotary protaper system will be used for canal preparation by crown down technique.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: will be assigned to rotary instrumentation.
Description: the canal will be prepared by conventional hedstorm files manually by step back technique.
Study: NCT06718764

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurosteer's single-channel EEG monitoring device
Description: Neurosteer device will be attached to participants forehead and readings will be collected for the duration of their NSICU stay.~Neurosteer auditory stimulation will be done 3-4 times a day to coincide with RASS and 1-2 times a day to coincide with CAM-ICU. The research team will correlate collected hourly RASS and CAM-ICU assessments with Neurosteer derived signals and parameters.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurosteer's single-channel EEG monitoring device
Description: Neurosteer device will be attached to participants forehead and readings will be collected for the duration of their NSICU stay.~Neurosteer auditory stimulation will be done 3-4 times a day to coincide with RASS and 1-2 times a day to coincide with CAM-ICU. The research team will correlate collected hourly RASS and CAM-ICU assessments with Neurosteer derived signals and parameters.
Study: NCT06714942

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Proprietary Blend of Ashwagandha
Description: One capsule (300mg) is taken twice daily with water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KSM-66 Ashwagandha root extract
Description: One capsule (300mg) is taken twice daily with water
Study: NCT06107894

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating lymphocytes
Description: After NMA Lymphodepletion, autologous TILs will be intravenous infused into patients.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating lymphocytes
Description: After NMA Lymphodepletion, autologous TILs will be intravenous infused into patients.
Study: NCT06714942

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule (300mg) is taken twice daily with water
Study: NCT06719427

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive brain stimulation that uses magnetic fields to stimulate specific areas of the brain. It is commonly used for the treatment of neurological and psychiatric disorders, such as major depressive disorder (MDD), anxiety, and sometimes ALS.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive brain stimulation that uses magnetic fields to stimulate specific areas of the brain. It is commonly used for the treatment of neurological and psychiatric disorders, such as major depressive disorder (MDD), anxiety, and sometimes ALS.
Study: NCT06719024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib Cream 1.5%
Description: a thin layer of the assigned topical to the selected lesions twice daily, maintaining at least an 8-hour interval between applications

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aqueous cream
Description: a thin layer of the assigned topical to the selected lesions twice daily, maintaining at least an 8-hour interval between applications
Study: NCT06717451

Intervention type: DEVICE
Intervention: Control-IQ Technology v1.5
Description: Tandem t:slim X2 insulin pump or Tandem Mobi insulin pump with Control-IQ technology v1.5.~Every month participants will receive a survey to complete assessments including any severe hypoglycemia or diabetic ketoacidosis events experienced since the prior assessment. Participants will also complete surveys related to patient reported outcomes at baseline, 6 months, and 12 months.
Study: NCT06719076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Healthcare Program (DHCP)
Description: Training for Type-II Diabetics~The program includes 6 structured training sessions, each session will delivered biweekly and lasting for 1 hour and 20 minutes , covering topics such as:~Week 1: Diabetes Education and Goal Setting Week 3: Nutrition and Meal Planning Week 5: Physical Activity and Exercise Week 7: Medication Management Week 9: Stress Management and Emotional Well-being Week 11: Review and Future Plans Time, Venue, and Interactive Activities Sessions will be held at the Federal General Hospital Basement, on Fridays, from 10:00 am to 11:20 am. Each session includes interactive elements, such as group discussions, practical exercises, and hands-on activities, to ensure participants are fully engaged and equipped to manage their T2DM diabetes.
Study: NCT06107894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 will be subcutaneous administrated for 14 days following TILs infusion.
Study: NCT06557564

Intervention type: GENETIC
Intervention: TruGraf liver gene expression
Description: Blood from the patients undergoing graft liver biopsy will be collected on the day of the liver biopsy, preferable prior to tissue collection or within 48 hours following the biopsy. Two specialized PaxGene tubes containing 2.5mL of blood each will be filled and will be sent to TGI laboratory in USA for processing, storage, and analysis using TGI's proprietary bioinformatics TruGraf will provide UHN with a Liver binary result: ACR or non-ACR. The results data will be batched and sent to UHN at agreed upon timepoints.
Study: NCT05537675

Intervention type: OTHER
Intervention: To evaluate the SUVmean (Standard Uptake Value) as a predictive factor of the tumor absorbed dose compared to the SUVmax
Description: Measure SUVmean (Standard Uptake Value) and SUVmax on PET exams

Intervention type: OTHER
Intervention: To evaluate the SUVmean (Standard Uptake Value) as a predictive factor of the tumor absorbed dose compared to the SUVmax
Description: Measure SUVmean (Standard Uptake Value) and SUVmax on PET exams
Study: NCT05705505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narazaciclib
Description: Orange tablets, each containing 40 mg or 120 mg of narazaciclib as narazaciclib monolactate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Tablet
Study: NCT06439732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acumen IQ cuff
Description: Use of Acumen IQ cuff for haemodynamic monitoring
Study: NCT06093243

Intervention type: OTHER
Intervention: data collection
Description: data collection
Study: NCT06159348

Intervention type: DIAGNOSTIC_TEST
Intervention: Anemia Diagnostic Assistant (ADA)
Description: The Anemia Diagnostic Assistant is non-invasive and simultaneously detects two markers of anemia, blood hemoglobin and the End-Tidal carbon monoxide levels. The device comprises an optical sensor module and ETCO breath sampling module.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum hemoglobin
Description: Venous blood will be drawn on the same day as the ADA was applied and sent to the hospital lab for hemoglobin analysis.
Study: NCT05184309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ConventioanalExercises
Description: Wand exercises and shoulder wheel exercises to increase the range of motion of the shoulder joint with 10 repetitions will be applied in CEG. Finger ladder exercises will be performed in the abduction and flexion position with 5 repetitions, holding the endpoint for 5 seconds. Stretching exercises with 5 repetitions will be applied in all directions for the limitation of movement, holding it for 20 seconds at the endpoint. Individuals performed conventional exercises twice a week for 6 weeks.
Study: NCT05758012

Intervention type: DRUG
Intervention: oxytocin
Description: Participants will be randomized to receive Oxytocin after delivery of the baby's head and shoulders

Intervention type: DRUG
Intervention: Carbetocin
Description: Participants will be randomized to receive Cabetocin after delivery of the baby's head and shoulders